Turn Therapeutics Inc. (TTRX) Stock Forecast
TTRX analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 5.00 / 5 from 2 analysts
- Price target
- $25.00 average of analyst targets
- Upside to target
- +136.5% from the latest close
- Next earnings
- November 12, 2026 EPS estimate $-0.02
- 52-week range
- $2.71 – $15.34
TTRX analyst ratings
2 analystsNumber of analysts at each rating.
TTRX price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
TTRX earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.09 | −$0.09 | −$0.08 | — | — | 2 |
| Current fiscal year (2026) | −$0.46 | −$0.52 | −$0.40 | −$0.12 | −283.3% | 2 |
| Next fiscal year (2027) | −$0.45 | −$0.51 | −$0.39 | −$0.46 | +2.2% | 2 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
TTRX revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | — | 1 |
| Current fiscal year (2026) | $250,000 | $0 | $500,000 | 0.0% | 2 |
| Next fiscal year (2027) | $2.5M | $0 | $5.0M | +900.0% | 2 |
TTRX EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
TTRX revenue: reported and forecast
TTRX EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.00 | −$0.03 | −$0.09 | −$0.09 | −$0.09 | — | 0 up · 0 down |
| Current fiscal year (2026) | $0.00 | −$0.09 | −$0.40 | −$0.40 | −$0.46 | — | 0 up · 0 down |
| Next fiscal year (2027) | $0.00 | −$0.32 | −$0.39 | −$0.39 | −$0.45 | — | 0 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
TTRX earnings surprises
Reported EPS vs the consensus estimate for the last 5 quarters; TTRX beat in 0 of 4.
What analysts expect from TTRX
2 analysts cover Turn Therapeutics; their consensus rating is strong buy (5.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $25.00, 136.5% above the latest close of $10.57. Analysts expect earnings of −$0.46 per share for 2026, −283.3% from a year earlier. For 2027 the average estimate is −$0.45 per share on revenue of $2.5 million. Turn Therapeutics beat the EPS estimate in 0 of the last 4 quarters.
Related: TTRX income statement, TTRX key metrics, TTRX chart. See the TTRX stock overview for the latest quote and news.
TTRX forecast FAQ
What is Turn Therapeutics's price target?
The average analyst price target for Turn Therapeutics is $25.00, 136.5% above the latest close of $10.57.
Is Turn Therapeutics a buy, hold or sell?
Of 2 analysts covering Turn Therapeutics, 2 rate it a strong buy, 0 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Turn Therapeutics's EPS forecast?
Analysts forecast −$0.46 per share for 2026 (range −$0.52 to −$0.40); for 2027 the estimate is −$0.45.
What is Turn Therapeutics's revenue forecast?
The average revenue estimate for 2026 is $0.2 million, growth of 0.0%; for 2027 it is $2.5 million.
When does Turn Therapeutics report earnings?
Turn Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 12, 2026 after the market closes; the EPS estimate is $-0.02.
Does Turn Therapeutics usually beat earnings estimates?
Turn Therapeutics reported EPS at or above the analyst estimate in 0 of the last 4 quarters.